MINERALYS THERAPEUTICS, INC. Operating Expenses
MINERALYS THERAPEUTICS, INC. (MLYS) reported Operating Expenses of $246.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $246.04M, a 426.33% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $45.34M, a 2.01% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $38.28M, a 26.05% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $41.13M, a 31.57% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. operating expenses for fiscal 2025 was $170.60M, a 11.33% decline from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. operating expenses for fiscal 2024 was $192.40M, a 127.27% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. operating expenses for fiscal 2023 was $84.66M, a 168.93% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. operating expenses for fiscal 2022 was $31.48M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $246.04M 10-Q · filed 2026-08-11 | $291.38M 10-Q · filed 2026-08-11 | $329.66M derived: sum of 3 quarters · filed 2026-08-11 | $370.79M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $45.34M 10-Q · filed 2026-05-06 | $83.62M derived: sum of 2 quarters · filed 2026-05-06 | $124.75M derived: sum of 3 quarters · filed 2026-05-06 | $171.50M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $38.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $79.41M derived: sum of 2 quarters · filed 2026-03-12 | $126.16M derived: sum of 3 quarters · filed 2026-08-11 | $170.60M 10-K · filed 2026-03-12 |
| 2025-09-30 | $41.13M 10-Q · filed 2025-11-10 | $87.88M derived: sum of 2 quarters · filed 2026-08-11 | $132.32M 10-Q · filed 2025-11-10 | $184.09M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $46.75M 10-Q · filed 2026-08-11 | $91.19M 10-Q · filed 2026-08-11 | $142.96M derived: sum of 3 quarters · filed 2026-08-11 | $203.07M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $44.45M 10-Q · filed 2026-05-06 | $96.21M derived: sum of 2 quarters · filed 2026-05-06 | $156.32M derived: sum of 3 quarters · filed 2026-05-06 | $201.49M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $51.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $111.87M derived: sum of 2 quarters · filed 2026-03-12 | $157.04M derived: sum of 3 quarters · filed 2026-03-12 | $192.40M 10-K · filed 2026-03-12 |
| 2024-09-30 | $60.11M 10-Q · filed 2025-11-10 | $105.27M derived: sum of 2 quarters · filed 2025-11-10 | $140.64M 10-Q · filed 2025-11-10 | $168.35M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $45.17M 10-Q · filed 2025-08-12 | $80.53M 10-Q · filed 2025-08-12 | $108.24M derived: sum of 3 quarters · filed 2025-08-12 | $134.51M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $35.36M 10-Q · filed 2025-05-12 | $63.07M derived: sum of 2 quarters · filed 2025-05-12 | $89.35M derived: sum of 3 quarters · filed 2025-05-12 | $105.08M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $27.71M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $53.98M derived: sum of 2 quarters · filed 2025-02-12 | $69.72M derived: sum of 3 quarters · filed 2025-02-12 | $84.66M 10-K · filed 2025-02-12 |
| 2023-09-30 | $26.27M 10-Q · filed 2024-11-12 | $42.01M derived: sum of 2 quarters · filed 2024-11-12 | $56.95M 10-Q · filed 2024-11-12 | $66.95M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $15.73M 10-Q · filed 2024-08-13 | $30.67M 10-Q · filed 2024-08-13 | $40.68M derived: sum of 3 quarters · filed 2024-08-13 | $48.10M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $14.94M 10-Q · filed 2024-05-09 | $24.95M derived: sum of 2 quarters · filed 2024-05-09 | $32.37M derived: sum of 3 quarters · filed 2024-05-09 | $38.85M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $10.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $17.43M derived: sum of 2 quarters · filed 2024-03-21 | $23.91M derived: sum of 3 quarters · filed 2024-03-21 | $31.48M 10-K · filed 2024-03-21 |
| 2022-09-30 | $7.42M 10-Q · filed 2023-11-07 | $13.90M derived: sum of 2 quarters · filed 2023-11-07 | $21.47M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $6.48M 10-Q · filed 2023-08-07 | $14.05M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $7.57M 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |